At Schrödinger, we are continuously improving our platform through rigorous scientific advancement. Check out the new features and usability improvements in Schrödinger’s 2024-3 software release: https://lnkd.in/eYix7f2C
Schrödinger
Software Development
New York, New York 45,866 followers
Transforming drug discovery and materials research
About us
Schrödinger’s industry-leading computational platform facilitates the research efforts of biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger also has wholly-owned and collaborative drug discovery programs in a broad range of therapeutic areas. Schrödinger is deeply committed to investing in the science and talent that drive its computational platform. Schrödinger was founded in 1990 and is engaged with customers and collaborators in more than 70 countries. We welcome you to visit our blog at www.extrapolations.com.
- Website
-
http://www.schrodinger.com
External link for Schrödinger
- Industry
- Software Development
- Company size
- 501-1,000 employees
- Headquarters
- New York, New York
- Type
- Public Company
- Founded
- 1990
Locations
Employees at Schrödinger
Updates
-
Schrödinger will announce second quarter 2024 financial results today, July 31, 2024 at 4:30 PM ET. Listen to the LIVE webcast here: https://lnkd.in/d3baFfsM
-
Schrödinger is excited to be participating in the 8th International Conference on Vibrational Optical Activity taking place August 4-8 in Bochum, Germany. Join us for a presentation by Art Bochevarov, Research Leader at Schrödinger, in which he will discuss the latest tools and algorithms Schrödinger has developed to aid in the selection of conformers for VCD spectra prediction, including Jaguar Spectroscopy. Learn more: https://hubs.li/Q02Jk6xY0
-
Today, Schrödinger announced a new initiative leveraging our computational platform to predict toxicology risk early in drug discovery. Initially funded by a $10 million grant from the Bill & Melinda Gates Foundation and enabled by NVIDIA’s AI technologies, the initiative aims to improve properties of novel drug development candidates and reduce their risk of binding to off-target proteins, which can be associated with serious side effects and lead to failure of the development program. Learn more about the new initiative in our press release: https://hubs.li/Q02J2Nmq0
-
AI/ML models are powerful tools for predicting diverse physical and chemical properties of small molecules. However, fine-tuning these models is resource-intensive and challenging to scale for numerous, frequently updated datasets. Join us on August 13th for a webinar introducing Schrödinger’s LiveDesign Learning, a new module in LiveDesign for training and deploying state-of-the-art AI/ML models with minimal manual intervention to offer rapid molecular property predictions. Register now: https://lnkd.in/g6QMpEkg
-
Are you attending this year’s International Conference on Atomic Layer Deposition? Don’t miss the talk on Tuesday, Aug 6th by Schrödinger's Dr. Simon Elliott, who will present our newly developed microkinetic model for ALD that can turn atom-by-atom mechanistic information into sticking coefficients and growth rates of films at the macroscopic scale. Learn more: https://hubs.li/Q02HPM9B0 #Schrodinger #DigitalChemistry #MaterialsScience #aldep #ALDALE2024
-
Looking to expedite your innovation timeline for display materials R&D? Join Schrödinger’s Hadi Abroshan in a live webinar on Aug 7th. We will explore the union of physics-based simulations, machine learning (ML), and cloud-native collaboration and informatics tools in revolutionizing R&D innovation for display materials. Register now: https://hubs.li/Q02H07450 #Schrodinger #DigitalChemistry #MaterialsScience #Organic Electronics
-
In a recent paper published in Nature Structural & Molecular Biology, researchers from UCB Pharma and University of Pittsburgh used FEP+ to refine and validate cryo-electron microscopy structures of SV2A and SV2B, proteins important in the treatment of epilepsy. FEP+ is Schrödinger’s proprietary, physics-based free energy perturbation technology for computationally predicting protein-ligand binding at an accuracy approaching experimental methods. In the paper, researchers describe using FEP+ to differentiate between correct and incorrect small molecule binding modes when solving cryo-EM complex structures. Read the paper: https://hubs.li/Q02FJGCH0 Learn more about FEP+: https://hubs.li/Q02FJKj30
-
Congratulations to our partner Morphic Therapeutic, a company that Schrödinger co-founded, on their planned acquisition by Eli Lilly. We are proud to have partnered side-by-side on the discovery of several programs, including MORF-057, that have the potential to transform patient care, and Morphic has been one of our largest and longest-standing customers in the biotech community.
Morphic today announced it has entered into an agreement to be acquired by Eli Lilly and Company (“Lilly”) in an all-cash transaction valued at approximately $3.2 billion. This exciting milestone marks a new phase for our company, and we eagerly anticipate the path forward for MORF-057 and oral integrin medicines under Lilly’s stewardship. Please read the full release as it contains important information: https://lnkd.in/eDdAEXzv
-
Are you attending the Institute of Food Technologists Conference taking place on July 14th – 17th in Chicago, Illinois? Join us for a presentation by Schrödinger's Jeffrey Sanders exploring how food scientists can leverage physics-based modeling and machine learning to make more informed decisions when formulating new foods and beverages with alternative proteins. Stop by our booth #2125 to discuss your food R&D challenges with our scientists. Learn more: https://hubs.li/Q02F2Bxb0 #Schrodinger #DigitalChemistry #MaterialsScience #Food